These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 16533786

  • 1. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
    Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT.
    Clin Cancer Res; 2006 Mar 01; 12(5):1593-8. PubMed ID: 16533786
    [Abstract] [Full Text] [Related]

  • 2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.
    Clin Cancer Res; 1999 Nov 01; 5(11):3488-99. PubMed ID: 10589763
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
    Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17426-31. PubMed ID: 17088539
    [Abstract] [Full Text] [Related]

  • 5. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
    Chin TW, Parry RL, Donahoe PK.
    Cancer Res; 1991 Apr 15; 51(8):2101-6. PubMed ID: 2009529
    [Abstract] [Full Text] [Related]

  • 6. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK.
    Development; 2006 Jun 15; 133(12):2359-69. PubMed ID: 16687449
    [Abstract] [Full Text] [Related]

  • 7. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
    Wallen JW, Cate RL, Kiefer DM, Riemen MW, Martinez D, Hoffman RM, Donahoe PK, Von Hoff DD, Pepinsky B, Oliff A.
    Cancer Res; 1989 Apr 15; 49(8):2005-11. PubMed ID: 2702642
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
    Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC.
    Cancer Res; 2003 Mar 15; 63(6):1389-97. PubMed ID: 12649204
    [Abstract] [Full Text] [Related]

  • 10. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
    Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA.
    Gynecol Oncol; 2008 Jan 15; 108(1):141-8. PubMed ID: 17988723
    [Abstract] [Full Text] [Related]

  • 11. Molecular biology of MIS and its receptors.
    Teixeira J, Donahoe PK.
    J Androl; 1996 Jan 15; 17(4):336-41. PubMed ID: 8889695
    [Abstract] [Full Text] [Related]

  • 12. Genetic studies of MIS signalling in sexual development.
    Jamin SP, Arango NA, Mishina Y, Behringer RR.
    Novartis Found Symp; 2002 Jan 15; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.
    Parry RL, Chin TW, Epstein J, Hudson PL, Powell DM, Donahoe PK.
    Cancer Res; 1992 Mar 01; 52(5):1182-6. PubMed ID: 1531323
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The müllerian inhibitor and mammalian sexual development.
    Behringer RR.
    Philos Trans R Soc Lond B Biol Sci; 1995 Nov 29; 350(1333):285-8; discussion 289. PubMed ID: 8570693
    [Abstract] [Full Text] [Related]

  • 16. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium.
    Wang J, Dicken C, Lustbader JW, Tortoriello DV.
    Fertil Steril; 2009 Apr 29; 91(4):1195-203. PubMed ID: 18328480
    [Abstract] [Full Text] [Related]

  • 17. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
    Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK.
    Mol Endocrinol; 2001 Jun 29; 15(6):946-59. PubMed ID: 11376113
    [Abstract] [Full Text] [Related]

  • 18. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
    Yin X, Ouyang S, Xu W, Zhang X, Fok KL, Wong HY, Zhang J, Qiu X, Miao S, Chan HC, Wang L.
    J Cell Sci; 2007 May 01; 120(Pt 9):1521-8. PubMed ID: 17452623
    [Abstract] [Full Text] [Related]

  • 19. Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance.
    Behringer RR, Cate RL, Froelick GJ, Palmiter RD, Brinster RL.
    Nature; 1990 May 10; 345(6271):167-70. PubMed ID: 2336108
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.